China Defends Decision To Revoke Viagra Patent

Law360, New York (September 6, 2004, 12:00 AM EDT) -- A leading official at China’s State Intellectual Property Office says the agency stands firmly behind its controversial decision to overturn Pfizer Inc.'s patent for Viagra.

The patent license originally granted in 2001 was invalidated after experts reviewed the case in response from complaints by more than 10 Chinese drug companies, deputy head of SIPO Zhang Qin said.

“The major reason for the patent office to do so was because the technological disclosure made in the patent's explanation document was insufficient,” Zhang told reporters at a news...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.